Literature DB >> 17199730

The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.

T Schöndorf, T Forst, C Hohberg, S Pahler, C Link, W Roth, A Pfützner, G Lübben, C Link, A Pfützner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17199730     DOI： 10.1111/j.1463-1326.2006.00582.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  7 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

2.  Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

Authors:  Andreas Pfützner; Markolf Hanefeld; Lida A Dekordi; Jürgen Müller; Iris Kleine; Winfried Fuchs; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

3.  Nervous System Expression of PPARγ and Mutant PPARγ Has Profound Effects on Metabolic Regulation and Brain Development.

Authors:  Madeliene Stump; Deng-Fu Guo; Ko-Ting Lu; Masashi Mukohda; Martin D Cassell; Andrew W Norris; Kamal Rahmouni; Curt D Sigmund
Journal:  Endocrinology       Date:  2016-08-30       Impact factor: 4.736

4.  Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.

Authors:  Yang Yu; Bao-Jian Xue; Shun-Guang Wei; Zhi-Hua Zhang; Terry G Beltz; Fang Guo; Alan Kim Johnson; Robert B Felder
Journal:  Hypertension       Date:  2015-06-22       Impact factor: 10.190

Review 5.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

6.  Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

Authors:  Jacob D Peuler; Laura E Phelps
Journal:  J Smooth Muscle Res       Date:  2015

Review 7.  A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

Authors:  Mozhgan Dorkhan; Anders Frid
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.